{
  "id": 16927141,
  "title": "Collaboration and Roadmaps Key to Capsid Accessibility",
  "url": "https://urgent.news/2026/10/28/collaboration-and-roadmaps-key-to-capsid-accessibility",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-28T16:00:11.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/bioprocessing/collaboration-and-roadmaps-key-to-capsid-accessibility/"
  },
  "original_language": "en",
  "account": "Collaboration and roadmaps are crucial for improving accessibility to capsids and their associated plasmids, according to Jorge Santiago-Ortiz, vice president of CMC & regulatory affairs at Apertura Gene Therapy. In his presentation at the Bioprocessing Summit in Boston, Santiago-Ortiz emphasized the importance of knowledge sharing regarding engineered capsids and their manufacturability to advance the field. The company's lead capsid, TfR1 CapX, has a manufacturing process that involves standard unit operations and commercially available reagents, taking place both internally and at contract manufacturer and other partner facilities in clinical batches of up to 500 L. Apertura Gene Therapy's success stems from considering manufacturability from the beginning and adapting standard analytics techniques for bespoke capsids. The company actively seeks to widen access to its technology through Material Transfer Agreements (MTAs) for academic researchers and for-profit companies, as well as offering advice on manufacturing, nonclinical development, regulatory strategies, and analytical development guidance. Santiago-Ortiz highlighted the company's proactive approach in providing support once a partnership is announced, aiming to be open and reachable to answer partners' questions. Additionally, Apertura Gene Therapy connects partners with complementary expertise to facilitate manufacturing through contract manufacturers. As the technology gains more adoption and manufacturing capability, the list of partners is expected to grow.",
  "summary": "Apertura says widening access to its TfR1 CapX capsid is a core philosophy, and that includes inviting a wide range of collaborations and supporting collaborators through advice and preclinical roadmaps. The post Collaboration and Roadmaps Key to Capsid Accessibility appeared first on GEN - Genetic Engineering and Biotechnology News .",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}